Trials / Completed
CompletedNCT00144495
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant human erythropoietin | 3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks |
| DRUG | recombinant human erythropoietin | 36000IU(s.c.)/week for 12 weeks |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2004-11-01
- Completion
- 2005-05-01
- First posted
- 2005-09-05
- Last updated
- 2009-02-02
Source: ClinicalTrials.gov record NCT00144495. Inclusion in this directory is not an endorsement.